[Federal Register Volume 85, Number 54 (Thursday, March 19, 2020)]
[Notices]
[Pages 15789-15790]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-05743]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket Nos. FDA-2020-N-0001, FDA-2020-N-0255, FDA-2020-N-0256, FDA-
2020-N-0259, FDA-2018-N-4337]
March 10 Through April 30, 2020, Public Meetings; Postponement,
Cancellation, or Remote Only
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration is announcing that certain
meetings involving the Center for Drug Evaluation and Research (CDER)
from March 10 through April 30, 2020, are postponed, cancelled, or
modified to take place remotely.
DATES: For dates that have been either postponed or cancelled, see
table 1 in the SUPPLEMENTARY INFORMATION section.
FOR FURTHER INFORMATION CONTACT: Kim Thomas, Center for Drug Evaluation
and Research, Food and Drug Administration, 10903 New Hampshire Ave.,
Bldg. 51, Rm. 6282, Silver Spring, MD 20993-0002, 301-796-2357,
[email protected].
SUPPLEMENTARY INFORMATION: Certain public meetings involving CDER from
March 10 through April 30, 2020, are postponed, cancelled, or modified
to take place remotely due to extenuating circumstances. The meetings
that are postponed or canceled as part of this notice are listed in
table 1. If a meeting is rescheduled, information about the rescheduled
meeting will be provided in the future. The meeting that will no longer
take place in person and instead take place by webcast only as part of
this notice is listed in table 2.\1\
---------------------------------------------------------------------------
\1\ Up-to-date information about public meetings involving CDER
is available on the internet at https://www.fda.gov/drugs/news-events-human-drugs/meetings-conferences-workshops-drugs.
[[Page 15790]]
Table 1--CDER Meetings Postponed or Cancelled
----------------------------------------------------------------------------------------------------------------
Federal Register
Meeting type Meeting title Original meeting date Docket No. citation
----------------------------------------------------------------------------------------------------------------
Public Meeting............ Patient-Focused Drug Mar. 10, 2020............ FDA-2020-N-0259. 85 FR 8877, Feb.
Development for 18, 2020.
Stimulant Use
Disorder.
Public Meeting............ Patient-Focused Drug Mar. 30, 2020............ FDA-2020-N-0255. 85 FR 8004, Feb.
Development for 12, 2020.
Vitiligo.
Public Meeting............ Scientific and Apr. 16, 2020............ FDA-2020-N-0001. 85 FR 14207,
Ethical Mar. 11, 2020.
Considerations for
the Inclusion of
Pregnant Women in
Clinical Trials.
Public Meeting............ Prescription Drug Apr. 22, 2020............ FDA-2018-N-4337. 85 FR 6547, Feb.
User Fee Act of 5, 2020.
2017; Electronic
Submissions and Data
Standards.
----------------------------------------------------------------------------------------------------------------
Table 2--CDER Meeting Held Remotely
--------------------------------------------------------------------------------------------------------------------------------------------------------
Federal Register
Meeting type Meeting title Original meeting date Docket No. citation Remote information
--------------------------------------------------------------------------------------------------------------------------------------------------------
Public Meeting.............. United States Food and Apr. 3, 2020................ FDA-2020-N-0256.... 85 FR 13659, Mar. https://www.fda.gov/
Drug Administration and 9, 2020. drugs/news-events-human-
Health Canada Joint drugs/health-canada-and-
Regional Consultation fda-joint-public-
on the International consultation-
Council for international-council-
Harmonisation of harmonisation-technical-
Technical Requirements 0.
for Pharmaceuticals for
Human Use.
--------------------------------------------------------------------------------------------------------------------------------------------------------
Dated: March 16, 2020.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2020-05743 Filed 3-18-20; 8:45 am]
BILLING CODE 4164-01-P